Department of Pathology, Oslo University Hospital, Norway, P.O. Box 4956 Nydalen, 0424, Oslo, Norway.
Oslo Center for biostatistics and epidemiology, Research Support Services, Oslo University Hospital, Norway, P.O. Box 4956 Nydalen, 0424, Oslo, Norway.
BMC Cancer. 2018 Feb 20;18(1):209. doi: 10.1186/s12885-018-4130-2.
Mammography screening is used to detect breast cancer at an early treatable stage, reducing breast cancer mortality. Traditionally, breast cancer has been seen as a disease with only progressive lesions, and here we examine the validity of this assumption by testing if incidence levels after introducing mammography screening can be reproduced assuming only progressive tumors.
Breast cancer incidence data 1990-2009 obtained from the initially screened Norwegian counties (Akershus, Oslo, Rogaland and Hordaland) was included, covering the time-period before, during and after the introduction of mammography screening. From 1996 women aged 50-69 were invited for biennial public screening. Using estimates of tumor growth and screening sensitivity based on pre-screening and prevalence screening data (1990-1998), we simulated incidence levels during the following period (1999-2009).
The simulated incidence levels during the period with repeated screenings were markedly below the observed levels. The results were robust to changes in model parameters. Adjusting for hormone replacement therapy use, we obtained levels closer to the observed levels. However, there was still a marked gap, and only by assuming some tumors that undergo regressive changes or enter a markedly less detectable state, was our model able to reproduce the observed incidence levels.
Models with strictly progressive tumors are only able to partly explain the changes in incidence levels observed after screening introduction in the initially screened Norwegian counties. More complex explanations than a time shift in detection of future clinical cancers seem to be needed to reproduce the incidence trends, questioning the basis for many over-diagnosis calculations. As data are not randomized, similar studies in other populations are wanted to exclude effect of unknown confounders.
乳腺 X 线筛查用于在可治疗的早期阶段检测乳腺癌,从而降低乳腺癌死亡率。传统上,乳腺癌被认为是一种仅具有进行性病变的疾病,在这里,我们通过检验在假设仅存在进行性肿瘤的情况下,引入乳腺 X 线筛查后能否重现发病率水平,来验证这一假设的有效性。
我们纳入了 1990-2009 年从最初接受乳腺 X 线筛查的挪威县(阿克什胡斯、奥斯陆、罗加兰和霍达兰)获得的乳腺癌发病率数据,涵盖了引入乳腺 X 线筛查之前、期间和之后的时间段。从 1996 年开始,年龄在 50-69 岁的女性每两年接受一次公共筛查。利用基于筛查前和患病率筛查数据(1990-1998 年)的肿瘤生长和筛查敏感性估计值,我们模拟了接下来的时间段(1999-2009 年)的发病率水平。
在重复筛查期间,模拟的发病率水平明显低于观察到的水平。改变模型参数后,结果仍然稳健。调整激素替代疗法的使用后,我们获得了更接近观察水平的结果。然而,仍存在显著差距,只有假设某些肿瘤发生退行性变化或进入明显难以检测的状态,我们的模型才能重现观察到的发病率水平。
具有严格进行性肿瘤的模型仅能部分解释在最初接受乳腺 X 线筛查的挪威县引入筛查后发病率水平的变化。为了重现发病率趋势,似乎需要比检测未来临床癌症的时间推移更复杂的解释,这对许多过度诊断计算的基础提出了质疑。由于数据不是随机的,因此希望在其他人群中进行类似的研究以排除未知混杂因素的影响。